Compare Globus Medical Inc. Class A Common Stock (GMED) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Vanguard High Dividend Yield ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Vanguard High Dividend Yield ETF trades at $158.92 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 9.8× Globus Medical Inc. Class A Common Stock's market cap, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Vanguard High Dividend Yield ETF for 140 Days on average.
| GMED | VYM | |
|---|---|---|
Market Cap | $10.25B | $100.80B |
Volume | 1,108,124 | 834,323 |
Sector | Health | — |
52-Week High | $96.82 | $167.03 |
52-Week Low | $58.33 | $138.43 |
Typical Hold Time | 0 Days | 140 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
VYM trades at $159.11, down slightly by 0.08% today, with a bullish technical signal from moving averages despite neutral oscillators. The ETF maintains strong sector diversification and a 2.42% dividend yield, though recent news highlights competition from alternatives like SCHD and IDV. Support levels are clustered around $157-158, with resistance at $160-161.
Outlook remains mixed; VYM offers steady income but faces pressure from higher-yielding or better-performing peers. Key risks include dividend cuts in holdings like Intel and Walgreens, while institutional sentiment leans cautious due to moderate growth prospects versus competing ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
